Aadi Bioscience has rebooted its operations, transforming from a commercial business into a preclinical biotech by offloading its approved product and…

The FDA has denied Zealand Pharma’s approval bid for glepaglutide—a possible challenger to Takeda’s Gattex—in short bowel syndrome (SBS), citing…

Pyxis Oncology is shelving a clinical-stage monoclonal antibody to focus on its lead antibody-drug conjugate (ADC) after sharing preliminary results…

To develop RNA medicines targeting a proprietary bundle of tumor antigens, Epitopea is tapping nucleic acid delivery specialist Genevant Sciences…

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the industry. Please…

Omeros is putting up its monoclonal antibody up for FDA approval—again. This time, the resubmission will be based on a…

After hitting the mark in a phase 2 of its investigational islatravir paired with Gilead’s lenacapivir, Merck & Co.'s islatravir…

KdT Ventures has signed off on a $608 million biobucks deal for NGM Biopharmaceuticals’ phase 2-ready metabolic-dysfunction associated steatohepatitis (MASH)…

A pair of Regeneron’s monoclonal antibodies have held their own against a commonly used anticoagulant in a phase 2 trial,…

Vertex has reported a phase 2 win that still dented confidence in its pain prospect suzetrigine. The trial linked the near-approval…